产前晚期早产糖皮质激素后血糖正常:多中心随机对照试验
这项多中心随机对照试验纳入了因预期早产在34 0/7至36 5/7周接受倍他米松的非糖尿病单胎孕妇,比较母体血糖筛查与治疗对胎儿C肽及新生儿低血糖的影响。中期分析后因无效而终止,母体血糖控制未改善胎儿C肽水平、新生儿低血糖或其他母婴结局。
要点
- 大多数非糖尿病孕妇接受晚期早产倍他米松后出现高血糖,但母体血糖筛查与治疗未改善胎儿C肽水平。
- 母体血糖控制组与期待管理组的新生儿低血糖发生率无显著差异(49% vs 51%,P=.83)。
- 中期分析后试验因无效而终止,作者认为对接受晚期早产糖皮质激素的非糖尿病孕妇进行血糖监测和治疗似乎无益。
核心结论
- 大多数非糖尿病孕妇在接受晚期早产倍他米松后出现高血糖,但母体血糖控制未改善胎儿代谢状态、新生儿低血糖或其他母婴结局。
- 因此,对接受晚期早产糖皮质激素的非糖尿病孕妇进行母体血糖监测和治疗似乎无益。
研究设计与样本
- 多中心随机对照试验(NCT03076775),纳入因预期早产在34 0/7周至36 5/7周接受倍他米松的非糖尿病单胎孕妇。
- 共筛查491例,163例(33%)符合条件,86例(53%)被随机分组(2017年6月至2021年2月)。
- 随机至母体血糖控制组的参与者接受空腹和餐后1小时或产时系列毛细血管血糖筛查,并根据指征给予胰岛素治疗;随机至期待管理组的参与者不接受任何血糖筛查或治疗。
- 主要结局为分娩时脐带血测定的胎儿C肽水平;次要结局包括其他胎儿代谢标志物和新生儿低血糖(血糖水平<40 mg/dL)。
- 样本量估计为144例,以在α=0.05下使用两样本t检验和1次中期分析提供>90%把握度显示C肽浓度降低1 ng/mL(±1.5 ng/mL);中期分析后试验因无效而终止。
主要发现
- 从倍他米松给药至分娩的中位间隔为24小时(四分位距13-96小时),两组间无差异(P=.82)。
- 随机至母体血糖控制组的参与者中82%出现高血糖:80%至少1次空腹血糖>95 mg/dL,75%至少1次餐后1小时血糖>140 mg/dL,80%至少1次产时血糖>110 mg/dL,15%至少1次血糖>180 mg/dL;胰岛素治疗后无母体低血糖发生。
- 与期待管理相比,母体血糖控制未影响中位胎儿C肽水平(1.02;四分位距0.52-1.85 vs 1.09;四分位距0.61-1.65;P=.97)或其他代谢标志物。
- 母体血糖控制也未影响新生儿低血糖(49% vs 51%;P=.83)或其他次要新生儿或母体结局。
- 未发现胎龄、随机时体重指数、倍他米松指征、倍他米松至分娩时长、母体种族或民族或新生儿性别对效应有修饰作用的证据;采用符合方案分析时结果不变。
临床怎么用
- 作者认为,对接受晚期早产糖皮质激素的非糖尿病孕妇进行母体血糖监测和治疗似乎无益。
局限性
- 中期分析后试验因无效而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Late preterm steroid administration can induce transient maternal and thus fetal hyperglycemia, which can increase production of fetal insulin and C-peptide. Infants delivered in this setting are subsequently at increased risk for hypoglycemia. Although maternal glycemic control before delivery is a key component of care for parturients with diabetes, this intervention has not been studied in the setting of late preterm steroid administration. OBJECTIVE: This study aimed to determine the effect of maternal screening for and treatment of hyperglycemia after late preterm steroid administration on fetal C-peptide levels and other metabolic markers. STUDY DESIGN: This was a multicenter, randomized trial (NCT03076775) of nondiabetic parturients with a singleton gestation receiving betamethasone at 34 0/7 weeks to 36 5/7 weeks for anticipated preterm birth. Participants randomized to maternal glycemic control received fasting and 1-hour postprandial or serial intrapartum capillary blood glucose screening with insulin treatment as indicated. Those randomized to expectant management did not receive any glucose screening or treatment. The primary outcome was fetal C-peptide level measured from umbilical cord blood at delivery. Secondary outcomes included other fetal metabolic markers and neonatal hypoglycemia (glucose level <40 mg/dL). Baseline characteristics and outcomes were compared between the groups. We estimated that we would need a sample size of 144 to provide >90% power to show a 1 ng/mL decrease in C-peptide concentration (±1.5 ng/mL) at ⍺=0.05 using a 2-sample t test and 1 interim analysis. After the interim analysis, the trial was stopped for futility. RESULTS: Of 491 screened parturients, 163 (33%) were deemed eligible and 86 (53%) were randomized to 1 of the treatment groups (June 2017 to February 2021). One person was lost to follow-up because of delivery at another hospital. Baseline characteristics were similar between groups. The median interval from betamethasone administration to delivery was 24 hours (interquartile range, 13-96 hours) and did not differ between groups (P=.82). Most (82%) randomized to maternal glycemic control had hyperglycemia: 80% had at least 1 fasting glucose level >95 mg/dL, 75% had at least one 1-hour postprandial glucose level >140 mg/dL, and 80% had at least 1 intrapartum glucose level >110 mg/dL. In addition, 15% had at least 1 glucose level >180 mg/dL. None had maternal hypoglycemia after insulin treatment. Compared with expectant management, maternal glycemic control did not affect the median fetal C-peptide level (1.02; interquartile range, 0.52-1.85 vs 1.09; interquartile range, 0.61-1.65; P=.97) or other metabolic markers. Maternal glycemic control also did not affect neonatal hypoglycemia (49% vs 51%; P=.83) or other secondary neonatal or maternal outcomes. There was no evidence of effect modification by gestational age or body mass index at randomization, indication for betamethasone, duration from betamethasone to delivery, maternal race or ethnicity, or neonatal sex. In addition, the results were unchanged in a sensitivity analysis using a per-protocol approach. CONCLUSION: Maternal hyperglycemia was observed in most nondiabetic parturients after receiving late preterm betamethasone. However, there was no improvement in fetal metabolic status, neonatal hypoglycemia, or other neonatal or maternal outcomes with maternal glycemic control. Therefore, maternal glucose surveillance and treatment does not seem to be beneficial in nondiabetic parturients receiving late preterm steroids.
引用
- Battarbee AN, Ye Y, Szychowski JM, et al. Euglycemia after antenatal late preterm steroids: a multicenter, randomized controlled trial. Am J Obstet Gynecol MFM. 2022. PMID: 35346889. doi:10.1016/j.ajogmf.2022.100625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。